Physician profile
Richard Capdevila
NPI 1518468941
$1,853.31
in general payments reported to CMS, 2019-2025
21 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.67 · 2024: $531 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.26 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.11 | 2024-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $234.43 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $189.18 | 2024-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $166.44 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $151.01 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $143.59 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $130.60 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $94.07 | 2024-2025 | |
| Glaxosmithkline, LLC. | $81.02 | 2024-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $77.95 | 2024-2025 | Dexcom G6 Transmitter |
| Baxter Healthcare | $62.67 | 2022 | |
| Sumitomo Pharma America, INC. | $48.38 | 2025 | Gemtesa |
| Insmed, INC. | $36.29 | 2025 | Brinsupri, Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $33.32 | 2025 | |
| Dynavax Technologies Corporation | $26.50 | 2025 | Heplisav-B |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.01 | 2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $23.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.01 | 2024 | Jardiance, Synjardy |
| Gilead Sciences, INC. | $19.71 | 2025 | |
| Abiomed | $18.68 | 2025 | |
| Abbvie INC. | $15.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Capdevila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.